Gadolinium
2022 (English)In: Handbook on the toxicology of metals: volume II: Specific metals / [ed] Gunnar F. Nordberg; Max Costa, Elsevier, 2022, 5, p. 267-274Chapter in book (Refereed)
Abstract [en]
Gadolinium (Gd) belongs to the rare-earth elements. Depending on the temperature, Gd is either ferromagnetic or paramagnetic. Gadolinium obtained its name from Johan Gadolin, the Finnish chemist who discovered gadolinite, a mineral that contains gadolinium. The specific properties of Gd make it suitable for certain applications in nuclear reactors as well as in medicine being the base for a chelate administered to patients as a contrast agent in magnetic resonance imaging. Such Gd chelates have been used for more than 30 years. During the past decades, there has been increasing knowledge about the potentially harmful effects of Gd chelates in patients with severe renal dysfunction. In such patients, there is a risk for a potentially life-threatening disease, nephrogenic systemic fibrosis. Precautions, restricting the use of Gd chelates in persons with severely impaired renal function have drastically decreased the occurrence of nephrogenic systemic fibrosis in the last decade. There has also been an increasing awareness of the fact that there is Gd deposition in the body even in patients without renal dysfunction and that this deposition is related partly to the cumulative number of doses given but also the chemical structure of the chelate. In this chapter, the physical and chemical properties of Gd and its related chelates, methods for detection, industrial and medical applications, human exposures, toxicity as well as a further description of potential side effects related to injection of Gd chelates are described.
Place, publisher, year, edition, pages
Elsevier, 2022, 5. p. 267-274
Keywords [en]
Contrast induced nephropathy, Gadolinium biomonitoring, Gadolinium chelates, Gadolinium deposition disease, Gadolinium induced respiratory distress syndrome, Gadolinium kinetics, Gadolinium toxicity, Gadoliniumin the environment, Nephrogenicsystemic fibrosis, Side effects of gadolinium chelates, Treatment of gadolinium toxicity
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:umu:diva-193330DOI: 10.1016/B978-0-12-822946-0.00010-6Scopus ID: 2-s2.0-85126417377ISBN: 9780128229460 (print)OAI: oai:DiVA.org:umu-193330DiVA, id: diva2:1647831
2022-03-292022-03-292023-05-25Bibliographically approved